Search

Displaying results 3231 - 3240 of 10000 in total
  1. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]

  2. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    However it inhibits taurocholate uptake only in the absence of sodium ions.

    Categories: Drugs Used in Diabetes
  3. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.

  4. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Mixtures: Relief and Nature Toothpast E Jasmine MintInternational brands: E-Capro, Kai Nai Yin
  5. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L50036] Three aflibercept biosimilars—Yesafili (aflibercept-jbvf)[L53043] and Opuviz (aflibercept-yszy)[L53038], approved in May 2024, and Ahzantive (aflibercept-mrbb)[L53048], approved in July 2024

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL
  6. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

  7. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  8. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]

  9. Drug

    Olaflur

    go.drugbank.com/drugs/DB13290
    Investigational

    Olaflur which is also referred to as elmex gel is an ingredient used in toothpaste which helps in the prevention of dental caries.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Poloxamer 407

    go.drugbank.com/drugs/DB11252
    Investigational

    Poloxamer 407 is used as an emulsifying agent and solubilizing agent in cosmetic and personal products such as contact lens cleaning solutions. … It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.

    Categories: Compounds used in a research, industrial, or household setting